Apellis Pharmaceuticals Stock Price To Earnings To Growth
| APLS Stock | USD 33.93 0.21 0.62% |
Apellis Pharmaceuticals fundamentals help investors to digest information that contributes to Apellis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Apellis Stock. The fundamental analysis module provides a way to measure Apellis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apellis Pharmaceuticals stock.
Apellis | Price To Earnings To Growth |
Apellis Pharmaceuticals Company Price To Earnings To Growth Analysis
Apellis Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Apellis Pharmaceuticals Price To Earnings To Growth | (0.30) X |
Most of Apellis Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Apellis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Apellis Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Apellis Pharmaceuticals is extremely important. It helps to project a fair market value of Apellis Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Apellis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Apellis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Apellis Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Apellis Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Apellis Pharmaceuticals has a Price To Earnings To Growth of -0.3 times. This is 142.25% lower than that of the Biotechnology sector and 109.55% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 106.13% higher than that of the company.
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Apellis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Apellis Fundamentals
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 4.29 B | ||||
| Shares Outstanding | 124.39 M | ||||
| Shares Owned By Insiders | 13.98 % | ||||
| Shares Owned By Institutions | 98.75 % | ||||
| Number Of Shares Shorted | 23.18 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 17.80 X | ||||
| Price To Sales | 5.94 X | ||||
| Revenue | 396.59 M | ||||
| Gross Profit | 69.79 M | ||||
| EBITDA | (495.21 M) | ||||
| Net Income | (528.63 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 110.93 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 1.94 X | ||||
| Cash Flow From Operations | (594.74 M) | ||||
| Short Ratio | 7.27 X | ||||
| Earnings Per Share | (2.03) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 45.75 | ||||
| Number Of Employees | 702 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 4.25 B | ||||
| Total Asset | 788.73 M | ||||
| Retained Earnings | (2.84 B) | ||||
| Working Capital | 518.74 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 788.73 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.